lomustine has been researched along with isotretinoin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carson, C; Dorigo, O; Fakhrai, H; Gjerset, R; Khaleghi, T; Koziol, J; Royston, I; Shawler, D; Shiftan, TA; Sobol, RE | 1 |
| Croteau, D; Mikkelsen, T | 1 |
2 review(s) available for lomustine and isotretinoin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Contraindications; Cranial Irradiation; Craniotomy; Dacarbazine; Disease Progression; Epidemiologic Methods; Glioblastoma; Humans; Isotretinoin; Lomustine; Palliative Care; Procarbazine; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Temozolomide; Treatment Outcome; Vincristine | 2001 |
3 other study(ies) available for lomustine and isotretinoin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Interleukin-2 gene therapy in a patient with glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cells, Cultured; Combined Modality Therapy; Fatal Outcome; Female; Fibroblasts; Genetic Therapy; Genetic Vectors; Glioblastoma; Humans; Injections, Subcutaneous; Interleukin-2; Isotretinoin; Lomustine; Magnetic Resonance Imaging; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Procarbazine; Radioimmunotherapy; Radiosurgery; Recombinant Fusion Proteins; Retroviridae; Salvage Therapy; T-Lymphocytes, Cytotoxic; Tamoxifen; Temporal Lobe; Transfection; Tumor Cells, Cultured; Vincristine | 1995 |